MedTrace Logo

To Assess the Efficacy and Safety of the Cardio Formulation in Reducing Oxidized LDL

NCT04317287 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2023-01-13

No results posted yet for this study

Summary

The purpose of this study is to assess the efficacy and safety of the Cardio formulation in reducing oxidized LDL \[(Ox LDL (low density lipoprotein)\] in overweight to mildly obese generally healthy adults.

Conditions

  • Oxidized Low Density Lipoprotein

Interventions

DIETARY_SUPPLEMENT

Cardio formulation

Tomato-based formulation with dietary supplement softgels

DIETARY_SUPPLEMENT

Placebo

Placebo softgels

Sponsors & Collaborators

  • Supplement Formulators, Inc.

    lead INDUSTRY

Principal Investigators

  • Andrew Swick, Ph.D · LIfe Extension

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-12-10
Primary Completion
2021-11-19
Completion
2021-11-19

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04317287 on ClinicalTrials.gov